Electra Therapeutics

Developing SIRP-targeted antibody therapies for immunological diseases and cancer

[Electra Therapeutics @ELECTRA_Biotech]

#RareDiseaseDay is a time to recognize those living with a rare disease and the scientific and clinical communities dedicated to finding new treatments. At Electra, we are proud to stand with you and remain dedicated to advancing ELA026 in the fight against #sHLH.

[Electra Therapeutics @ELECTRA_Biotech]

Today at #ASH25, results of the completed Phase 1b study of ELA026 for the treatment of secondary hemophagocytic lymphohistiocytosis (#sHLH) will be presented. 
https://t.co/zZlNSrvWvN

[Electra Therapeutics @ELECTRA_Biotech]

Be sure to check out a new interview with our CEO Kathy Dong in Inside Precision Medicine. Kathy talks about #sHLH, a rare inflammatory disease, and the encouraging clinical trial results for ELA026.
https://t.co/lJLZ7BNveT

[Electra Therapeutics @ELECTRA_Biotech]

Join us at #ASH2024 on December 9th, 2:45pm PT for an oral presentation on ELA026. We will be sharing clinical data from our completed phase 1b study of ELA026 in #sHLH.
https://t.co/3DnmqAzzR4

[Electra Therapeutics @ELECTRA_Biotech]

#sHLH is a life-threatening disease with no approved treatments. #FastTrack designation underscores the urgent need for effective therapeutic options and accelerates our development path to make a transformative impact on patients and their families.
https://t.co/X4pqBt6Z21

[Electra Therapeutics @ELECTRA_Biotech]

We're excited to announce orphan drug designation for ELA026, a first-in-class antibody therapy targeting SIRP with a novel mechanism of action to treat secondary HLH (sHLH).
#sHLH
https://t.co/RzD4Dxxrol

[Electra Therapeutics @ELECTRA_Biotech]

Electra's lead candidate, ELA026, shows promising results for improved survival in secondary HLH triggered by malignancy. Our phase 1b results presented at #EHA2024

[Hagop Kantarjian,MD @DrHKantarjian]

New encouraging secondary #HLH treatment
https://t.co/snlO5lCIZ9
Abhishek Maiti @MDAndersonNews #Leukemia
@EHA_Hematology
#EHA2024

[Hagop Kantarjian,MD @DrHKantarjian]

New encouraging secondary #HLH treatment
https://t.co/snlO5lCIZ9
Abhishek Maiti @MDAndersonNews #Leukemia
@EHA_Hematology
#EHA2024

[Electra Therapeutics @ELECTRA_Biotech]

ELA026 demonstrated a high overall response rate across a range of #sHLH patients. In patients with the poorest prognosis, those with malignancy-associated HLH, early treatment with ELA026 resulted in 100% ORR and improved survival.
#EHA2024
https://t.co/aLsbpFdgk9

[Electra Therapeutics @ELECTRA_Biotech]

Clinical data for our lead candidate ELA026 is selected as 1 of 6 abstracts for the late-breaking oral session at #EHA2024. Data is from our ongoing Phase 1b study in patients with #sHLH, a life-threatening inflammatory disease.
https://t.co/DHc7223ba6

[Electra Therapeutics @ELECTRA_Biotech]

We are delighted to have these exceptional leaders on our team: Dr. Graham Parry as CSO and Dr. Kim-Hien Dao as CMO. Their extensive experience and expertise in drug development will be invaluable at this time of great momentum for Electra.
https://t.co/sfxO6WRnsT

[Electra Therapeutics @ELECTRA_Biotech]

We recently had the honor of hosting patient advocates who shared incredibly moving stories of their loved one’s journeys with #sHLH. Our team was inspired by their passion and dedication to raising awareness and finding a treatment.

[Electra Therapeutics @ELECTRA_Biotech]

#RareDiseaseDay is a time to acknowledge the remarkable resilience of individuals around the world living with rare conditions, as well as their dedicated family members and friends.
#rarediseaseday2024
#RareDiseasesDay

[Electra Therapeutics @ELECTRA_Biotech]

Hope to see you at #ASH23 where we'll be presenting Phase 1b clinical data for our lead drug candidate ELA026 for secondary hemophagocytic lymphohistiocytosis (#sHLH), a life-threatening inflammatory disease.
#Histiocytosis
https://t.co/0BHgI8scdk

[Electra Therapeutics @ELECTRA_Biotech]

We’re excited to highlight ELA026, our antibody in the clinic for secondary hemophagocytic lymphohistiocytosis (#sHLH), in an oral presentation today during the Presidential Symposium at the Histiocyte Society Annual Meeting.
#HSMtg2023
#Histiocytosis
https://t.co/re4qg4lZDU

[Electra Therapeutics @ELECTRA_Biotech]

Join the Electra team in supporting #HistiocytosisAwareness month and recognizing people living with histiocytic disorders. We are committed to advancing ELA026 for the treatment of #sHLH. #HistioBlueRibbonRun, #histiorunchallenge, #histiocytosisawareness, #iknowhistio

[Electra Therapeutics @ELECTRA_Biotech]

We are honored to have been recognized as the Most Innovative Start-up Company at last night's 7th Annual #CitelineAwards! The judges made note of our collaborative research and educational work with trial sites in their evaluation of the nominees.

[Electra Therapeutics @ELECTRA_Biotech]

We're honored to have been selected by Citeline as one of the Most Innovative Start-up Companies in 2022 and will continue innovating for rare-disease patients.
#CelebrateCiteline
https://t.co/BwsM3c49Ca

[Electra Therapeutics @ELECTRA_Biotech]

For us, everyday is Rare Disease Day as we work to transform the treatment landscape for patients most in need.
#ShareYourColours
#RareDiseaseDay2023
#RareDisease

[Electra Therapeutics @ELECTRA_Biotech]

Without treatment, secondary hemophagocytic lymphohistiocytosis (sHLH) can rapidly progress to multi-organ failure and death.
#MasteringSIRP
https://t.co/XGCXETV6he